PND10 A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA  by Victor, TW & Barlas, S
A376 Abstracts
management in adult patients with refractory epilepsy in Spain.
METHODS: A cross-sectional and retrospective study was
designed. Male and female adult patients (above 18 years) with
refractory epilepsy were enrolled in neurology medical settings
between March and September 2005 in Spain. Health care and
non-health care resources were collected and total costs calcu-
lated according with published prices for year 2005. Quality-of-
life, level of anxiety and depression, health state, concomitant
medications and comorbidity history and treatment of epilepsy
were also recorded. A secondary analysis including a forward
stepwise multivariate regression model exploring possible
explicative variables was performed. RESULTS: Seven-hundred-
sixty-two consecutive patients [728 evaluables (95.5%); 50.8%
males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were
included through the country at epilepsy units, neurology out-
patient clinics and hospital outpatient clinics. A moderate
explicative model was built; adjusted R-square = 0.24 (F = 26.6,
p < 0.0001). Presence of mental retardation and social function
domain of the QOLIE-10 were the variables with most explica-
tive weight of total cost in these patients; standardized estimates
of 0.303 and 0.175, respectively [â coefﬁcient (standard error)
of 6675.0 (826.8) and 53.5 (12.7), p < 0.001 in both cases
respectively]. Health status on a 0–100 mm-VAS (standardized
estimate; 0.142), need for additional non-neurological hospital
assistance (0.118), previous episode of secondarily generalized
seizures (0.102), health care at neurology outpatient clinics
(0.083), and documented etiology of epilepsy (0.096) were all
found to be signiﬁcant explicative variable, all of them p < 0.05.
CONCLUSIONS: This secondary analysis found a broad sources
of drivers of costs in patients with refractory epilepsy in Spain,
with mental retardation and social function domain of QOLIE-
10 (the higher the score the higher the cost) being responsible
for a substantial part of total cost.
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OBJECTIVE: To estimate the cost-effectiveness of pramipexole
versus no treatment in patients with moderate to very severe rest-
less legs syndrome (RLS) in Sweden taking the societal perspec-
tive. METHODS: A cost-utility Markov model was developed
that included ﬁve health states (no, mild, moderate, severe and
very severe RLS) based on the International RLS Study Group
Rating Scale scores. The probability of moving between health
states was derived from the phase III, randomized, double-blind
pramipexole trials in RLS. To comprehensively estimate quality-
adjusted life years (QALYs) several approaches were taken to
map the IRLS to the EQ-5D including Delphi panel, patient
survey and published literature. Treatment patterns were esti-
mated with a physician expert panel. 2005 unit costs were
derived from Swedish government sources. Both one-way and
probabilistic sensitivity analyses were conducted. RESULTS:
Over a one-year time period, treatment with pramipexole
reduced overall costs by SEK 1191 (approximately €128) per
patient and was associated with a gain of 0.035 QALYs relative
to no treatment when using utilities from the Delphi panel.
Pramipexole’s dominance from the societal perspective against
the no treatment alternative was robust to sensitivity analysis.
Sensitivity analyses included variation in health care provider
costs, different utility assumptions, and an extension of the
model to a ﬁve-year time period. CONCLUSIONS: Active treat-
ment of RLS with pramipexole is preferred over no treatment
for patients with moderate to very severe RLS in Sweden.
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OBJECTIVE: To estimate the cost-utility of levodopa-carbidopa
and levodopa-carbidopa-entacapone in the treatment of Parkin-
son disease in the Mexican Institute of Social Security in Mexico.
METHODS: Cost-utility analysis. Use of resources information
was obtained from a retrospective cohort and was validated by
a Mexican expert panel. Costs were estimated from ﬁnancial
information from IMSS, and are reported in US 2006 dollars.
The source of utility information, measured in QALYs, and 
transition probabilities was a meta-analysis and a Mexican
expert panel. Study perspective used: public health services
provider (IMSS); ﬁve years time horizon, 3% real discount rate.
A decision tree with a Bayesian approach and a Markov model
were used. Mean cost-utility, incremental ratios and net health
beneﬁts were estimated. The sensitivity analysis included one-
way, two-way, threshold and probabilistic with Monte Carlo
simulation. RESULTS: Cost per utility unit for levodopa-
carbidopa was $5623 and for levodopa-carbidopa-entacapone,
$5168. Incremental cost-utility ratio using levodopa-carbidopa
as a comparator was $1585. Independently of WTP, levodopa-
carbidopa-entacapone had larger net health beneﬁts than 
levodopa-carbidopa. In the ﬁve years analysis, levodopa-
carbidopa-entacapone showed 12.8% more utility in relation-
ship to levodopa-carbidopa, with 3.5% more costs. The cost per
utility unit with levodopa-carbidopa-entacapone had an accu-
mulated decrease of 18.4% during the period of time analyzed.
The acceptability curves and the component analysis of the
ellipse graph showed that with the actual cost that the IMSS is
investing in the treatment of Parkinson disease, the cost-utility
proportion of levodopa-carbidopa-entacapone would be 80%.
CONCLUSIONS: Levodopa-carbidopa-entacapone had the
lowest cost per unit of success in the treatment of patients with
Parkinson disease compared with levodopa-carbidopa. Cost per
additional utility unit of levodopa-carbidopa-entacapone was
$1585. At the end of the follow-up levodopa-carbidopa-enta-
capone reduced annual health care costs to a greater extent than
levodopa-carbidopa and provided better quality of life per
patient.
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OBJECTIVE: The objective of this study was to evaluate the
indirect evidence of menstrual migraine headache by examining
migraine headache prevalence as a function of age. Investigators
have reported that the risk of migraine headache decreases with
age but have not fully described the nature of the decline based
on sex. METHODS: This study was based on data from the
adult sample of the 2003 National Health Interview Survey
(NHIS). The study sample consisted of 17,394 females and
A377Abstracts
13,396 males representing 212.7 million American adults aged
18 to 85+ years. Nonparametric regression models were
employed to express migraine prevalence as a function of age
separately for each sex group. The salient characteristics of the
ﬁtted functions were evaluated by examining the ﬁrst and second
derivatives, corresponding to the velocity and the acceleration of
prevalence over the age continuum. RESULTS: Study results
suggest that migraine prevalence increases with age until about
34 years, where it reaches a maximum, then starts declining until
75 years where it reaches a plateau for both sexes. For females,
the greatest rate of decline in migraine prevalence starts at 41
years and continues until age 63 where it reaches its minimum.
The rate of decline in migraine prevalence for males, on the other
hand, seems to be decreasing in a smooth monotonic fashion
starting age 34 and reaches the female rate of change at 78 years.
The dramatic change in both the slope and the curvature of the
function for females around the perimenopausal age range war-
rants attention. CONCLUSIONS: These ﬁndings provide indi-
rect evidence for the phenomenon of menstrual migraine. The
inﬂection points on the female curve correspond to the age range
of perimenopause and menopause in U.S. women. These inﬂec-
tion points are not observed on the male curve.
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OBJECTIVES: Phase III clinical trials showed novel drugs intro-
duced in the 1990s modiﬁed the natural history (NH) of relaps-
ing-remitting onset deﬁnite multiple sclerosis (MS). A Nova
Scotia Phase IV “real world” observational study conﬁrmed the
short-term effectiveness of these disease modifying therapies
(MS-DMT), measured by Extended Disability Status Scale
(EDSS) increase avoided per patient per year. This analysis pro-
jects these short-term results over a 20-year horizon to estimate
long-term health outcomes of MS-DMT. METHODS: A proba-
bilistic Markov model estimated EDSS progression for NH and
MS-DMT cohorts with relapsing-remitting onset MS over a 20-
year horizon. The model was based on 591 patients receiving
MS-DMT from the Dalhousie MS Research Unit, stratiﬁed into
three subgroups by ﬁnal classiﬁcation and disability severity: 1)
mild relapsing-remitting MS (RRMS), 2) mild secondary-pro-
gressive MS (SPMS) and 3) mild or moderate SPMS. Health out-
comes were measured as EDSS disability adjusted life years
(DALYs) avoided per patient compared to NH. Relative beneﬁt
was deﬁned as DALY burden avoided relative to expected
DALYs given NH. The baseline analysis was a “best-case” sce-
nario with full compliance for 20 years. RESULTS: The model
found statistically signiﬁcant beneﬁt in all three subgroups.
Among the mild severity subgroups, there were 1.7 (95%
CI:1.2–2.2) DALYs avoided among RRMS patients and 2.6
(1.5–3.6) DALYs avoided among SPMS patients, for a combined
beneﬁt of 1.9 (1.2–3.2) DALYs avoided, or a 42% (20%–91%)
relative beneﬁt. Among the mild or moderate SPMS patients
there were 1.1 (0.3–1.9) DALYs avoided (14%; 3–30%).
Overall, the combined cohort had a beneﬁt of 1.5 (0.5–2.1)
DALYs avoided (29%; 6–63%). CONCLUSIONS: MS-DMT
can have signiﬁcant long-term beneﬁt in terms of DALYs
avoided, particularly in mild subgroups. This analysis is the ﬁrst
to model long-term change in mean EDSS, rather than delayed
time to speciﬁc EDSS endpoints, and may help guide MS-DMT
coverage decisions.
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OBJECTIVES: To describe and compare the domains and psy-
chometric properties of selected Patient Reported Outcomes
(PROs) instruments, neuropsychological and cognitive, devel-
oped and/or used in patients with Parkinson’s disease (PD).
METHODS: A systematic literature review of published studies
was conducted using MEDLINE (1990–2006), EMBASE
(1990–2006) and the Mapi Research Trust databases. Only
studies describing the development or use of a referenced instru-
ment assessing Health-Related Quality Of Life (HRQL), Activi-
ties of Daily Living (ADL), Fatigue/sleep, Neuropsychological
and cognitive measures were included in the review. Instruments
were selected if they were speciﬁcally developed for Parkinson’s
disease, or used in clinical trials and for which psychometric
properties were available. Caregiver reports were not included.
RESULTS: Sixty instruments were identiﬁed and 35 were
selected for in-depth review. Seven questionnaires measured
HRQL (2 generic and 5 PD speciﬁc). Of these, the PDQUALIF
and the PDQ-39 are well validated but are not always sensitive
to changes in RCTs. Four instruments assessed ADL/disability,
with the UPDRS being generally used as a primary endpoint in
RCTs. Six instruments measured sleep or fatigue, most of them
have been validated in PD patients and are sensitive to change.
Two symptoms (motor & non-motor) scales were selected, but
lack evidence of good psychometric properties. Four psycholog-
ical instruments and 12 neuropsychological/cognitive instru-
ments were also selected. Most of these were not validated in PD
patients and failed to demonstrate their sensitivity to change in
clinical trials. CONCLUSIONS: The selected PRO instruments
are very heterogeneous in their levels of validation, psychomet-
ric properties and sensitivity to change in clinical trials, depend-
ing on the dimension measured. For HRQOL, ADL/Disability
and Sleep, reliable measures are available whereas advances 
are still needed to assess symptoms, psychological well-being or
cognition.
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OBJECTIVES: Treatment of epilepsy is still challenging to the
scientiﬁc community. Usually, these patients require more than
one drug. Hence satisfaction with antiepileptic drugs becomes a
major goal, as it is of crucial relevance for seizures control and
patient wellbeing, particularly at the level of anxiety, depression
and quality of life. This study assessed the psychometric prop-
erties of a recently developed questionnaire of Treatment Satis-
faction (SATMED-Q) in subjects with refractory epilepsy.
METHODS: patients with refractory epilepsy from epilepsy and
neurology outpatient clinics, representative of the national dis-
tribution in Spain were included. Sociodemographic, anthropo-
metric data, and the SATMED-Q (Treatment Satisfaction), and
HAD (Anxiety and Depression) questionnaires were collected.
Reliability and validity were determined. Factor analysis was
used to check the instrument original structure. RESULTS: A
sample of 768 consecutive patients [average age of 40.5 (13.5)
years, 50.8% males and 24.3 (13.4) years of disease evolution]
